21 January 2021 - NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis- aiming to avoid irreversible damage as early as possible.

Galapagos today welcomed the news that NICE has issued a final appraisal determination recommending the use of the daily oral pill, Jyseleca (filgotinib) on the National Health Service in England for the treatment of eligible adult patients with moderate to severe active rheumatoid arthritis. 

It is the first time in the UK that an advanced therapy has been recommended in people with moderate rheumatoid arthritis, offering thousands more the potential to achieve remission earlier - potentially slowing the irreversible damage and life-limiting symptoms rheumatoid arthritis can cause.

Read Galapagos press release